Stage: clinical T >= . cm, T or T, N-, M; participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study (i.e., >= . cm operable breast cancer) and no tumor is human epidermal growth factor receptor  (HER)-positive (+ by immunohistochemistry [IHC] or in situ hybridization [ISH] amplified >= .); in this circumstance, the investigator must determine which will represent the target lesion to be assessed for response; this should remain consistent throughout the study; the target lesion should be selected on the basis of its size (lesion with the longest diameter) and suitability for accurate repetitive measurements
Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show subsequent evidence of substantial size increase to be deemed a target lesion
Patients must have at least ONE of the following: ) Bone disease, ) Any amount of neuroblastoma tumor cells in the bone marrow, ) At least one soft tissue lesion that meets criteria for a TARGET lesion, ) At least one non-target soft tissue lesion that is not measurable, but had a biopsy positive for neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment or is MIBG avid
Lesions that have had definitive external beam radiotherapy or locoregional therapies such as radiofrequency (RF) ablation or brachytherapy must show evidence of progressive disease to be deemed a target lesion
Prior therapy is allowed provided the following are met: at least  weeks since prior locoregional therapy including surgical resection, radiotherapy, or ablation; provided target lesion has increased in size by % or more or the target lesion was not treated with locoregional therapy
The lesion is suitable for repeat measurement using computerized tomography/magnetic resonance imaging (CT/MRI). Lesions that have had external beam radiotherapy (EBRT) or locoregional therapy must show radiographic evidence of disease progression based on RECIST . to be deemed a target lesion.
Presence of at least  non-target lesion suitable for multiple biopsies while on treatment.
Prior therapy is allowed provided the following are met: at least  weeks since prior locoregional therapy including surgical resection, chemoembolization, radiotherapy, or ablation. Provided target lesion has increased in size by % or more or the target lesion was not treated with locoregional therapy. Patients treated with palliative radiotherapy for symptoms will be eligible  week after treatment as long as the target lesion is not the treated lesion
Prior irradiation to the planned radiation target lesion.
Subjects must have an area of tumor amenable to excisional biopsy for the generation of TIL separate from, and in addition to, a target lesion to be used for response assessment.
Has measurable disease, defined as at least  tumor that fulfills the criteria for a target lesion
Must have a tumor lesion safely accessible for biopsy per the investigators discretion; while a soft tissue metastasis is preferred for a biopsy, a bone metastasis is allowed for biopsy as long as enough cores can be obtained; a biopsied lesion cannot be used for target lesion for response assessment
Radiotherapy to a target lesion within the past  months prior to baseline imaging unless that area has demonstrated progression
Measurable disease (at least one target lesion)
Presence of at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by irRECIST
The target lesion is one that either has never received external beam radiation or has been previously irradiated and has since demonstrated progression; any local irradiation of the target lesion or any non-target lesions via external beam, conformal or stereotactic radiation treatments must have occurred more than  weeks prior to study drug administration; any full cranial-spinal radiation, whether or not a target lesion is included in the field, must have occurred more than  months prior to study drug administration
Patients with at least two liver tumor lesions with at least one with a diameter of  cm or bigger, which is amendable for (super-)selective TATE as the target lesion. Alternatively, patients with one intra-hepatic lesion of  cm or bigger and exhapetic lesion(s) are also acceptable.
At least  lesion accessible for biopsy in addition to the target lesion
A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) \r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
Subjects must have at least one target lesion in breast/chest wall/axilla which is amenable to application of high intensity focused ultrasound:\r\n* The distance from the skin: A targetable portion of the tumor must be ?  mm from the skin\r\n* The rib cage should not be in the prefocal ultrasound path or behind the target area of the lesion (minimum distance from the posterior aspect of the target area to rib cage must be at least  mm)\r\n* Subjects tumor must be larger than  mm in the anterior-posterior dimension (measured by ultrasound)\r\n* Subjects tumor must be greater than or equal to . cubic centimeters
Presence of at least one target lesion (distinct from treatment lesion and outside of treatment lesion radiation field) evaluable for response by RECIST .
Patients must have at least one focus of metastatic disease that is amenable to pre- and on-treatment biopsy and be willing to undergo this; ideally the biopsied lesion should not be one of the target measurable lesions, although this can be up to the discretion of the investigators
Patients must have at least one focus of metastatic disease that is amenable to pre- and on-treatment biopsies; ideally the biopsied lesion should not be one of the target measurable lesions, although this can be up to the discretion of the investigators
Subjects must have measurable disease (at least one target lesion) as defined by RECIST .; target lesions must not be chosen from a previously irradiated field unless there has been radiographically and/or pathologically documented tumor progression in that lesion prior to enrollment
Measurable disease by RECIST . criteria (at least one target lesion outside of previous radiation fields or progressed within a previous radiation field)
Subjects with planned radiation therapy to a target lesion will be excluded
Measurable metastatic sites of disease outside of the target lesion undergoing palliative radiation based on RECIST . as assessed by the investigator
Subjects must have at least  lesion that is measurable by irRECIST\r\n* A previously irradiated lesion can be considered a target lesion if the lesion is well defined, measurable per irRECIST, and has clearly progressed\r\n* Subjects undergoing fresh tumor biopsies must have additional non-target lesions that can be biopsied at acceptable risk as judged by the investigator or if no other lesion suitable for biopsy, then an irRECIST target lesion used for biopsy must be >=  cm in longest diameter
A minimum of one measurable lesion defined as:\r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria In Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
Patients must have anticipated residual measurable disease after resection of target lesion(s) for TIL growth
A minimum of one measurable lesion defined as:\r\n* Meeting the criteria for measurable disease according to irRECIST criteria\r\n* For patients with skin metastases, lesions selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
The subject must have at least  measurable target lesion >= mm in longest dimension that is in an anatomic location treatable by MR-HIFU. Note that for this study, lesions in bone WILL be considered measurable provided they meet the other criteria by Response Evaluation Criteria in Solid Tumors (RECIST) and are confirmed to be metabolically active on baseline studies by either metaiodobenzylguanidine (MIBG) uptake (for neuroblastomas) or positron emission tomography (PET) avidity. Target lesions should be located so that they can be adequately heated by a hyperthermia treatment cell with a diameter of up to  mm, centered at a depth of  to  mm from the skin. There should be no staples, implants, extensive scarring, or other highly ultrasound absorbing or reflecting tissue in the expected beam path. For the first  patients enrolled on this study only, the lesion must be located in the extremities or pelvis to be considered treatable by MR-HIFU.
Target lesion that has been previously irradiated
Patients must have at least one biopsiable measurable metastatic melanoma, lesion >  cm and must be amenable to undergoing serial biopsies through the course of therapy; this lesion must not be documented as one of the target lesions
At least one measurable disease site that meets target lesion requirements
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must have subsequently grown unequivocally to be deemed a target lesion.
Radiotherapy to the target lesion within the past  months prior to baseline imaging
Target lesion size for re-irradiation must be =<  vertebral bodies
The position and accessibility of the target lesion allows for the safe administration of multiple ablation cycles or deployments to achieve a probe dwell time of ?  minutes.
Symptomatic patients in need of surgery to the target lesion
Patients enrolled in the dose-expansion part of the trial must have at least one lesion that may qualify as a target lesion based on the RECIST . criteria.
Complete obstruction of portal venous flow to the segment of liver that includes the target lesion
For patients with skin metastases, lesions selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
Have at least one target (ie, measurable) intracranial CNS lesion (? mm in longest diameter by contrast enhanced magnetic resonance imaging [MRI]). Lesions previously treated by stereotactic radiosurgery (SRS) or surgical resection should not be included as a target lesion. Lesions previously treated with whole brain radiation therapy (WBRT) may be included as a target lesion if () the last administration of WBRT was > months prior to the first dose of AP and () unequivocal radiological progression of the lesion has been observed. Expansion Cohort  Specific Inclusion Criteria:
Inability to adequately perform volumetric measurement of at least  target lesion (e.g., due to the presence of artifacts from cochlear or auditory brainstem implants, ill-defined tumor margins resulting from the juxtaposition of tumors abutting each other, or sequela from prior irradiation to the target lesion); Note: patients with cochlear or auditory brainstem implants may participate if a target lesion can be accurately assessed
Radiation therapy for the target lesion in the  months preceding inclusion in the study
The Target Lesion must be determined to be amenable to percutaneous injection by the treating physician.
Target Lesion(s) must not be contiguous with, encompass or infiltrate major blood vessels.
Lesions that have had radiotherapy must show subsequent radiographic evidence of increase in size by at least % to be deemed a target lesion.
Patients must have at least ONE of the following: ) Bone disease, ) Any amount of neuroblastoma tumor cells in the bone marrow, ) At least one soft tissue lesion that meets criteria for a TARGET lesion, ) At least one non-target soft tissue lesion that is not measurable, but had a biopsy positive for neuroblastoma and/or ganglioneuroblastoma at any time prior to enrollment or is MIBG avid
Diagnosis of an advanced solid tumor malignancy; there must be a target tumor which is measurable, palpable or clearly identifiable under ultrasound or radiographic guidance and amenable to percutaneous injection of C. novyi-NT spores; the targeted lesion must have a longest diameter ?  cm and <  cm and be measurable as defined by RECIST . criteria; the target lesion must not be located in either the thoracic, abdominal or pelvic cavities or in the brain; there must be no clinical, no functional, and no radiographic evidence of bone involvement at the site of the target lesion
Multifocal or multicentric breast cancer is allowed if all the lesions are biopsied and are HER positive; largest lesion will be assigned the target lesion
One or more measurable lesion(s) (\target lesion[s]\) that can be accurately measured in at least  dimension
American Joint Committee on Cancer (AJCC) clinical stage I with T > . cm, stage II or III invasive breast cancer; participants with multicentric or bilateral disease are eligible if at least one lesion meets stage eligibility criteria for the study and no tumor is HER-positive; in this circumstance, the investigator must determine which will represent the target lesion to be assessed for response; this should remain consistent throughout the study; the target lesion should be selected on the basis of its size (lesion with the longest diameter) and suitability for accurate repetitive measurements
Residual measurable disease after resection of target lesion(s) for TIL growth
Residual measurable disease after resection of target lesion(s) for TIL growth
Lesions that have had external beam radiotherapy or locoregional therapies such as radiofrequency ablation must show evidence of subsequent progressive disease (substantial size increase of ? %) to be deemed a target lesion.
Radiotherapy that involves the lung or mediastinum within  months prior to chemotherapy. (Note: there is no washout period for palliative radiation to non-target organs other than the lung or mediastinum. If radiation was to an intended target lesion within  months of baseline imaging studies, and the lesion is progressing within this time frame it may be considered as a target lesion after review and discussion with the Sponsor.)
The target lesion is one that either has never received external beam radiation or has been previously irradiated and has since demonstrated progression; any local irradiation of the target lesion or any non-target lesions via external beam, conformal or stereotactic radiation treatments must have occurred more than  weeks prior to study drug administration; any full craniospinal radiation, whether or not a target lesion is included in the field, must have occurred more than  months prior to study drug administration
A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
No interim time prior to study entry is required following prior radiation therapy (RT) for non-target lesions; however, patients must not have received radiation for a minimum of  weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response; lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma; palliative radiation is allowed to sites that will not be used to measure response during this study
Subjects whose only target lesion(s) is in bone will be excluded
A minimum of one measurable lesion defined as: \r\n* Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)\r\n* Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)
Radiotherapy to the target lesion within the past  months prior to baseline imaging
Measurable disease with >=  target lesion
Patients must have at least one target lesion to be used to assess response on this protocol as defined by RECIST .
In patients with multicentric or bilateral invasive breast cancers, all sampled lesions must be hormone receptor-positive and HER-negative and have an Oncotype Dx recurrence score =< ; one lesion (typically the largest) should be designated as the target lesion for which response to the neoadjuvant therapy will be judged
Patient has biopsy-proven diagnosis of cancer and radiographic evidence of bone metastasis to serve as target lesion(s)
Unstable bone in the target lesion requiring surgical stabilization prior to radiation
At least one \target lesion\ to be used to assess response, as defined by RECIST . criteria;
Radiotherapy =<  weeks prior to registration, except if to a non-target lesion only
Prior radiation to a target lesion is permitted only if there has been clear progression of the lesion since radiation was completed; if patient receives single dose radiation for palliation or radiation to non-target lesion, they may immediately proceed to registration without waiting; acute adverse events from radiation must have resolved to =< Common Terminology Criteria for Adverse Events (CTCAE) v . grade 
At least one targetable lesion appropriate for palliative SBRT and one non-target lesion
Radiation therapy to a study target lesion within  months
Lesions previously treated with radiotherapy or locoregional therapy must show radiographic evidence of disease progression to be deemed a target lesion.
Medical contraindication to biopsy of target lesion
the radiation field does not encompass a target lesion
Has ? lesion that meets the criteria for measurable, as defined by RECIST ., and is appropriate for selection as a target lesion, as determined by local site investigator/radiology assessment
Patients must have at least ONE of the following: ) Bone disease, ) Any amount of neuroblastoma tumor cells in the bone marrow, ) At least one soft tissue lesion that meets criteria for a TARGET lesion.
Patients must have at least one additional lesion (measurable by RECIST v. or non-target) identified as a control untreated lesion to be left untreated and followed for response.
At least one uni-dimensional HCC target lesion assessable by CT or MRI according to RECIST .
Subjects enrolled in Part B must have at least  lesion that may qualify as a target lesion
Lesions that have had radiotherapy must show subsequent radiographic evidence of increased size to be deemed a target lesion.
Diagnosis of an advanced solid tumor malignancy. There must be a target tumor which is measureable, palpable or clearly identifiable under ultrasound or radiographic guidance and amenable to percutaneous injection of C. novyi-NT spores. The targeted lesion must have a longest diameter ?  cm and ?  cm and be measurable as defined by RECIST . criteria. The target lesion must not be located in either the thoracic, abdominal or pelvic cavities or in the brain. There must be no clinical, no functional, and no radiographic evidence of bone involvement at the site of the target lesion.
Part : Patients must have target (? cm diameter) or non-target lesion cancer that is accessible for core biopsies before starting on study and after one cycle of treatment.
Patients can have previous brain metastasis that was completely surgically resected if the previously resected lesion is at least  cm from target lesion(s) for this study; the location of the previous resection cavity is determined by the post-resection MRI
Mirels Criteria Score ? . (specific to the target humeral lesion and subject to minimum VAS score requirements)
Mirels Score <  (specific to target humeral lesion).
Measurable metastatic disease with a target lesion that has increased in size by % in maximal dimension either during or within six months after treatment with chemotherapy using a gemcitabine containing regimen
At least one soft tissue site that meets criteria for a TARGET lesion defined by:
where Target Lesions should be at least  mm from any other lesion
Radiation directed at target lesion within  days of registration
The participants target lesion must be limited to a single biopsy-confirmed tumor; presence of other pulmonary nodules, which may represent synchronous early lung cancer, is allowed as long as no additional therapy is anticipated within  months following protocol therapy
Lesions that have had radiotherapy must show evidence of progressive disease based on RECIST . to be deemed a target lesion.
At least one target lesion. In patients with prior loco-regional therapy, the target lesion(s) must be located in area(s) outside previous treatment
Radiotherapy to the target lesions within  months prior lymphodepleting chemotherapy. A lesion with unequivocal progression may be considered a target lesion. There is no washout period for palliative radiation to non-target lesions.
Radiographically or clinically measurable disease with at least  target lesion per International Working Group (IWG) criteria for malignant lymphoma.
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of subsequent progressive disease (substantial size increase of ?%) to be deemed a target lesion.
Request for formalin-fixed, paraffin-embedded (FFPE) archival tumor specimens if available and willingness of the participant to undergo mandatory fresh tumor biopsy unless determined medically unsafe or not feasible; a note from the study team should be provided documenting availability of tissue; if a target lesion is biopsied at screening, this lesion must be followed as non-target lesion after the biopsy unless it is the patients only target lesion; if there is only one target lesion, it should be followed as a target lesion regardless\r\n* The archival specimen should contain adequate viable tumor tissue\r\n* The specimen may consist of a tissue block (preferred and should contain the highest grade of tumor) or at least  unstained serial sections; fine-needle aspiration, brushings, cell pellet from pleural effusion, bone marrow aspirate/biopsy are not acceptable\r\n* Fresh tumor biopsy at progression will be required in cases where patients experience relapse after an initial response if medically safe
Target lesion of any size
Target lesion located . cm or more away from visceral pleura based on the needle path
Presence of at least one target lesion amenable to percutaneous tumor biopsy in the judgment of interventional radiology
No prior local therapy to target lesion
Presence of at least one target lesion detected by standard staging scans that, in the judgment of study investigators, would be amenable to hyperpolarized C- pyruvate/metabolic MR imaging:\r\n* Soft tissue/visceral organ target lesions must measure at  cm in long axis diameter on computed tomography (CT) or MRI\r\n* Target lesions in the bone must be visualized by CT or MRI (lesions present only on bone scan do not qualify)\r\n* For patients with target lesion in prostate/prostatic bed:\r\n** No contra-indications to endorectal coil insertion (e.g., patients with a prior abdominoperineal resection of the rectum or latex allergy).\r\n** No prior local treatment to the selected lesion; patients who have received prior radiation or ablative therapy to the prostate will be required to have biopsy-proven evidence of disease recurrence following completion of local therapy
Concomitant medications for treatment of the target lesion
Prior radiation therapy to the target lesion
Concomitant medications for treatment of the target lesion
Prior radiation therapy to the target lesion
Radiographically or clinically measurable disease with greater than or equal to (>=)  target lesion per IWG criteria for malignant lymphoma.
Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST . to be deemed a target lesion.